Speaker: Professer Adam Mead
Duration: 6.41
Prof Mead discusses important considerations for the treatment of CML. He summarises baseline assessments, as recommended by the BSH 2020 guidelines on the diagnosis and management of CML, and covers the importance of calculating Sokal, ELTS and CCI scores at baseline.
Duration: 4.17
Covered in Chapter 2 is the importance of patient monitoring, as recommended in the BSH 2020 guidelines, and practical solutions to address gaps in the current management of CML. Prof Mead shares best practices from his professional experience.
Duration: 5.58
In Chapter 3, Prof Mead covers the BSH 2020 treatment strategy for patients with CML based on response. For those who do not respond to first-line therapy, key considerations for second-line TKI selection are summarised – which include mutational analysis, assessment of comorbidities, and evaluation of adverse events experienced with first-line TKI.
Adam Mead is a Professor of Haematology at the MRC Weatherall Institute of Molecular Medicine, University of Oxford. His research is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. The overarching aim of his research group is to improve the management of MPN,CML and related conditions through better characterisation and therapeutic targeting of malignant stem and progenitor cell populations. He is the lead clinician for myeloid neoplasms in the Thames Valley Strategic Cancer Network and is the Principal or Chief Investigator of over 30 clinical trials in MPN and CML. His laboratory has a particular interest in the development and application of single cell genomics techniques to analyse malignant stem cell populations.
Log in/register to download the CML checklist; a resource for HCPs to aid discussions with patients on disease status and wider comorbidities that could impact treatment decisions.
Available on-demand, watch Professor Mhairi Copland present two patient case studies on the management of CP CML using BOSULIF. Content recorded from CPD approved webinar 'The Evolution of CML Management in 2023'.
BSH, British Society of Haematology; CCI, Charlson Comorbidity Index; CML, chronic myelogenous leukaemia; CP, chronic phase; ELTS, EUTOS long-term survival; MPN, myeloproliferative neoplasms; TKI, tyrosine kinase inhibitor
PP-PFE-GBR-2809. March 2021
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024